Fluorouracil,Leucovorin and Irinotecan Combined with Intra-Arterial Hepatic Infusion of Drug-Eluting Beads Preloaded with Irinotecan in Unresectable Colorectal Liver Metastases: Side Effects and Results of a Concomitant Treatment Schedule. Clinical Investigation

Abstract

Aim

Safety evaluation of concomitant systemic chemotherapy and liver chemoembolization in patients with colorectal cancer.

Patients and Methods

Seven patients with metastases confined to the liver were included and stratified into two groups, depending of dosage of systemic chemotherapy. The first group received systemic chemotherapy (FOLFIRI) with 20% dose reduction, and the second group received the full dose of the same chemotherapy. In both groups, chemoembolization of liver metastases with drug-eluting bead irinotecan (DEBIRI) was performed following the application of systemic chemotherapy. The toxicity profiles of the two groups were compared.

Results

Of the 7 patients included, 4 received the reduced systemic chemotherapy dose and 3 received the full chemotherapy dose. DEBIRI was performed in all 7 patients. The main toxicities observed in the reduced chemotherapy dose group were leukopenia (25%), anorexia (75%), diarrhea (25%), vomiting (25%), right upper abdominal quadrant pain (100%) and elevated serum amylase level (25%). Main toxicities observed in the full chemotherapy dose group were anorexia (66.6%), vomiting (33.3%), right upper abdominal quadrant pain (100%), and elevated serum amylase level (66.6%). There were no significant differences between the two groups (P = 0.78541).

Conclusions

Patients with isolated liver metastases from a colorectal primary can safely be treated with DEBIRI chemoembolization and a full dose of systemic chemotherapy (FOLFIRI).